Search

This study aims to investigate differences in serum ischemia-modified albumin (IMA) and adjusted IMA levels among cases of healthy intrauterin pregnancies, threatened abortions, and missed abortions. In this prospective case-control study, a total of 90 participants were included, distributed into three groups: missed abortion (n = 30), threatened abortion (n = 30), and intrauterin healthy pregnancy (n = 30). IMA and adjusted IMA values were calculated for each group. Our findings revealed no significant differences in serum IMA and adjusted IMA concentrations among the three groups. Additionally, there were no correlation observed between IMA levels, adjusted IMA levels, and maternal age, body mass index (BMI), white blood cell (WBC) count, neutrophil count, lymphocyte count, platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to lymphocyte ratio (PLR), mean corpuscular volume (MCV), and red cell distribution width (RDW). The study concludes that IMA lacks a reliable capacity to differentiate between potential healthy intrauterine pregnancies, threatened abortions, or missed abortions during the first trimester. These results highlight the need for exploring alternative biomarkers that may offer greater specificity in distinguishing various pregnancy outcomes in early gestation. [ABSTRACT FROM AUTHOR]

Preeclampsia is a progressive and pregnancy-specific disorder and it affects multiorgan systems. Although the pathophysiology of preeclampsia is still unknown, it involves both maternal and fetal/placental factors. Endothelial cell damage and impaired endothelial cell function play an important role in the development of preeclampsia. Adipokines have role in many pathophysiological processes in the body. Subfatin is a newly discovered adipokine, if dysfunctional may cause endothelial damage. This study investigated whether subfatin levels can be used as a predictive marker for possible pathophysiology. This study was designed as prospective case-control study. Fifty-six pregnant women who had delivered between gestational age of 37th and 41th weeks with singleton pregnancies in a tertiary reference hospital were included. Pregnant women with a diagnosis of preeclampsia were defined as the case group and normotensive pregnants without a diagnosis of preeclampsia were defined as the control group. There was no statistically significant difference in terms of age, BMI, gravidity and parity between the groups. Mean systolic and diastolic blood pressures were observed higher in case group than control group. Subfatin level of control group was found higher than case group and this difference was statistically significant. Subfatin level = 49.32 ng/mL with 78.6% sensitivity and 71.4% specificity was found significant for case group. Subfatin may have a role in endothelial dysfunction and take part in pathophysiology of preeclampsia. According to this study we suggest that as a newly diagnosed adipokine, subfatin may be helpful in predicting preeclampsia development in pregnant women. [ABSTRACT FROM AUTHOR]

Aim: This study aimed to explore the potential of delta neutrophil index (DNI) as a predictive biomarker for the development of endometrial cancer (EC) in women with endometrial intraepithelial neoplasia (EIN). Material and Methods: This retrospective study included 139 women diagnosed with EIN who underwent surgery between 2019 and 2022. Demographic data, medical history, and laboratory parameters, including DNI, were collected from the patients' medical records. Patients with other types of cancer, a history of steroid use, inflammatory, hematologic, or autoimmune diseases, or missing data were excluded. The patients' pathology reports were reviewed, and patients were divided into three groups by the final pathological diagnosis, benign (n=64), EIN (n=66), and EC (n=39). Results: The mean DNI level of the EC group was found to be significantly higher than the EIN and benign groups (4.85±2.31, 2.31±0.89, 1.48±1.03, p<0.001, respectively). The optimal cut-off value of DNI was determined as 2.75% with 82.1% sensitivity and 73.8% specificity. DNI levels >2.75% were found to be associated with an 11.56-fold (95% CI: 4-59-29.09, p<0.001) increased risk of EC. Smoking and postmenopausal status were also identified as independent risk factors for EC. Patients with smoking had a 4.13-fold (95% CI: 1.54-11.01, p=0.005), and postmenopausal status had a 2.8-fold (95% CI: 1.87-9.04, p=0.034) increased risk of EC. Conclusion: The results of this study suggest that DNI may be a useful biomarker for predicting the risk of EC. The results also confirm that smoking and postmenopausal status are independent risk factors for EC. [ABSTRACT FROM AUTHOR]